Wedbush restated their outperform rating on shares of Vigil Neuroscience (NASDAQ:VIGL – Free Report) in a report released on Friday morning, Benzinga reports. Wedbush currently has a $23.00 target price on the stock.
VIGL has been the topic of several other reports. JMP Securities assumed coverage on shares of Vigil Neuroscience in a research report on Wednesday, October 18th. They set an outperform rating and a $23.00 target price on the stock. Mizuho cut their price objective on Vigil Neuroscience from $15.00 to $13.00 in a research note on Thursday, August 10th. Finally, HC Wainwright reiterated a buy rating and set a $24.00 price target on shares of Vigil Neuroscience in a report on Thursday, September 14th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of Moderate Buy and an average target price of $19.20.
Vigil Neuroscience Stock Performance
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. State Street Corp lifted its position in Vigil Neuroscience by 16.3% during the 3rd quarter. State Street Corp now owns 21,374 shares of the company’s stock worth $195,000 after buying an additional 3,000 shares in the last quarter. Royal Bank of Canada acquired a new stake in shares of Vigil Neuroscience in the second quarter valued at approximately $33,000. Barclays PLC raised its position in Vigil Neuroscience by 3.7% in the 4th quarter. Barclays PLC now owns 105,893 shares of the company’s stock worth $1,324,000 after purchasing an additional 3,730 shares during the last quarter. California State Teachers Retirement System acquired a new position in Vigil Neuroscience during the 2nd quarter worth $50,000. Finally, Wells Fargo & Company MN lifted its holdings in Vigil Neuroscience by 6,988.4% during the 2nd quarter. Wells Fargo & Company MN now owns 6,096 shares of the company’s stock worth $57,000 after buying an additional 6,010 shares in the last quarter. 71.80% of the stock is owned by institutional investors and hedge funds.
About Vigil Neuroscience
Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
- Five stocks we like better than Vigil Neuroscience
- What is Put Option Volume?
- The most upgraded stocks in November have two things in common
- 10 Best Airline Stocks to Buy
- Monday.com rocked earnings like it’s the weekend
- What is a Death Cross in Stocks?
- Plan to own one retailer? Make it this one
Receive News & Ratings for Vigil Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vigil Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.